Having trouble accessing articles? Reset your cache.

GAO finds little evidence Priority Review program spurring drug development

There is little evidence that the U.S. rare pediatric disease Priority Review voucher program has incentivized development of medicines, according to a Government Accountability Office report.

The report could influence Congress, which is facing a Sept. 30 deadline to reauthorize the voucher program. If not renewed, the program would end in September 2022.

FDA rewards a PRV upon the approval of a

Read the full 622 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE